US Bancorp DE Purchases 2,469 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

US Bancorp DE increased its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXGFree Report) by 19.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,212 shares of the company’s stock after acquiring an additional 2,469 shares during the period. US Bancorp DE’s holdings in 10x Genomics were worth $851,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. UMB Bank n.a. grew its holdings in shares of 10x Genomics by 51.6% during the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after purchasing an additional 266 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new stake in 10x Genomics during the 4th quarter worth about $66,000. Van ECK Associates Corp increased its position in 10x Genomics by 23.4% in the 4th quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock valued at $107,000 after acquiring an additional 362 shares in the last quarter. Powell Investment Advisors LLC bought a new position in shares of 10x Genomics in the fourth quarter worth about $200,000. Finally, Bleakley Financial Group LLC acquired a new position in shares of 10x Genomics during the fourth quarter worth approximately $234,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Benjamin J. Hindson sold 4,087 shares of 10x Genomics stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $99,314.10. Following the transaction, the insider now owns 350,055 shares in the company, valued at approximately $8,506,336.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other 10x Genomics news, CFO Justin J. Mcanear sold 2,936 shares of the stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $71,344.80. Following the completion of the transaction, the chief financial officer now owns 146,203 shares in the company, valued at approximately $3,552,732.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 4,087 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total value of $99,314.10. Following the completion of the sale, the insider now owns 350,055 shares in the company, valued at $8,506,336.50. The disclosure for this sale can be found here. Insiders sold 11,900 shares of company stock worth $289,170 over the last ninety days. 10.03% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. The Goldman Sachs Group cut their price target on 10x Genomics from $30.00 to $26.00 and set a “sell” rating on the stock in a research note on Wednesday, May 1st. Bank of America decreased their price target on 10x Genomics from $45.00 to $36.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. Barclays dropped their price objective on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. Finally, Jefferies Financial Group initiated coverage on shares of 10x Genomics in a research note on Monday. They issued a “hold” rating and a $24.00 target price on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $46.62.

View Our Latest Analysis on 10x Genomics

10x Genomics Stock Down 3.1 %

Shares of NASDAQ:TXG opened at $21.51 on Wednesday. The company has a 50 day moving average price of $28.70 and a two-hundred day moving average price of $39.99. 10x Genomics, Inc. has a 52 week low of $21.14 and a 52 week high of $63.57.

10x Genomics (NASDAQ:TXGGet Free Report) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). The business had revenue of $141.01 million during the quarter, compared to analysts’ expectations of $142.24 million. 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.44) EPS. As a group, equities research analysts anticipate that 10x Genomics, Inc. will post -1.55 earnings per share for the current fiscal year.

About 10x Genomics

(Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

See Also

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.